{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:06:45Z","timestamp":1750910805873,"version":"3.41.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.soc.2024.12.002","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T20:48:42Z","timestamp":1736282922000},"page":"253-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Therapy and Surgical Management of Peritoneal Mesothelioma"],"prefix":"10.1016","volume":"34","author":[{"given":"Ricardo E.","family":"Nunez-Rocha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex C.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.soc.2024.12.002_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/cancers15010229","article-title":"Contemporary trends in malignant peritoneal mesothelioma: incidence and survival in the United States","volume":"15","author":"Calthorpe","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.soc.2024.12.002_bib2","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1245\/s10434-021-10048-4","article-title":"Cytoreductive surgery plus HIPEC with and without NIPEC for malignant peritoneal mesothelioma: a propensity-matched analysis","volume":"28","author":"Sugarbaker","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.12.002_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/oxfordjournals.aje.a009093","article-title":"Analysis of current trends in United States mesothelioma incidence","volume":"145","author":"Price","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"19","key":"10.1016\/j.soc.2024.12.002_bib4","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.3390\/cancers15194704","article-title":"Malignant peritoneal mesothelioma: an in-depth and up-to-date review of pathogenesis, diagnosis, management and future directions","volume":"15","author":"Karpes","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.soc.2024.12.002_bib5","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: a review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2024.12.002_bib6","doi-asserted-by":"crossref","first-page":"114582","DOI":"10.1016\/j.envres.2022.114582","article-title":"Multistage carcinogenesis: impact of age, genetic, and environmental factors on the incidence of malignant mesothelioma","volume":"230","author":"Moolgavkar","year":"2023","journal-title":"Environ Res"},{"issue":"8","key":"10.1016\/j.soc.2024.12.002_bib7","doi-asserted-by":"crossref","first-page":"103644","DOI":"10.1016\/j.esmoop.2024.103644","article-title":"Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms","volume":"9","author":"Benzerdjeb","year":"2024","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.soc.2024.12.002_bib8","doi-asserted-by":"crossref","first-page":"101600","DOI":"10.1016\/j.esmoop.2023.101600","article-title":"Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies","volume":"8","author":"Dietz","year":"2023","journal-title":"ESMO Open"},{"issue":"15","key":"10.1016\/j.soc.2024.12.002_bib9","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.soc.2024.12.002_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-015-0485-1","article-title":"BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma","volume":"13","author":"Alakus","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"35","key":"10.1016\/j.soc.2024.12.002_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A\u00a0subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.soc.2024.12.002_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.6004\/jnccn.2023.7055","article-title":"Principles of surgical management of peritoneal mesothelioma","volume":"21","author":"Steadman","year":"2023","journal-title":"J\u00a0Natl Compr Cancer Netw JNCCN"},{"issue":"11","key":"10.1016\/j.soc.2024.12.002_bib13","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/cncr.32870","article-title":"The Chicago Consensus on peritoneal surface malignancies: management of peritoneal mesothelioma","volume":"126","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.soc.2024.12.002_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.21037\/atm.2017.03.96","article-title":"Malignant peritoneal mesothelioma: a review","volume":"5","author":"Kim","year":"2017","journal-title":"Ann Transl Med"},{"issue":"9","key":"10.1016\/j.soc.2024.12.002_bib15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.soc.2024.12.002_bib16","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","article-title":"Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival","volume":"25","author":"Verma","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2024.12.002_bib17","doi-asserted-by":"crossref","first-page":"1015884","DOI":"10.3389\/fsurg.2022.1015884","article-title":"Diffuse malignant peritoneal mesothelioma: a review","volume":"9","author":"Sun","year":"2022","journal-title":"Front Surg"},{"issue":"3","key":"10.1016\/j.soc.2024.12.002_bib18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/030089160308900307","article-title":"Clinical presentation of peritoneal mesothelioma","volume":"89","author":"Acherman","year":"2003","journal-title":"Tumori"},{"issue":"64","key":"10.1016\/j.soc.2024.12.002_bib19","first-page":"1087","article-title":"Localized visceral invasion of peritoneal mesothelioma causing intestinal obstruction: a new clinical presentation","volume":"52","author":"Sethna","year":"2005","journal-title":"Hepato-Gastroenterology"},{"issue":"2","key":"10.1016\/j.soc.2024.12.002_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1245\/s10434-006-9192-8","article-title":"Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion","volume":"14","author":"Baratti","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2024.12.002_bib21","first-page":"32","article-title":"Peritoneal mesothelioma: a review","volume":"9","author":"Bridda","year":"2007","journal-title":"MedGenMed"},{"issue":"5","key":"10.1016\/j.soc.2024.12.002_bib22","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1245\/s10434-012-2236-3","article-title":"Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures","volume":"19","author":"Low","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.soc.2024.12.002_bib23","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1007\/s00330-003-1851-6","article-title":"CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature","volume":"13","author":"Kebapci","year":"2003","journal-title":"Eur Radiol"},{"issue":"6","key":"10.1016\/j.soc.2024.12.002_bib24","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1148\/rg.226025125","article-title":"Best cases from the AFIP. Malignant peritoneal mesothelioma","volume":"22","author":"Busch","year":"2002","journal-title":"Radiographics"},{"issue":"4","key":"10.1016\/j.soc.2024.12.002_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jso.21055","article-title":"Consensus statement on peritoneal mesothelioma","volume":"98","author":"Deraco","year":"2008","journal-title":"J\u00a0Surg Oncol"},{"issue":"24","key":"10.1016\/j.soc.2024.12.002_bib26","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","article-title":"Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy","volume":"21","author":"Feldman","year":"2003","journal-title":"J\u00a0Clin"},{"issue":"4","key":"10.1016\/j.soc.2024.12.002_bib27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.soc.2024.12.002_bib28","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.25640","article-title":"A\u00a0novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database","volume":"117","author":"Yan","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.soc.2024.12.002_bib29","first-page":"e247031","article-title":"Systemic therapy options for peritoneal mesothelioma","volume":"22","author":"Tanvetyanon","year":"2024","journal-title":"J\u00a0Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.soc.2024.12.002_bib30","doi-asserted-by":"crossref","first-page":"21357","DOI":"10.1038\/s41598-021-00831-4","article-title":"Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort","volume":"11","author":"Cedres","year":"2021","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.soc.2024.12.002_bib31","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.002_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.soc.2024.12.002_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Cancer Amst Neth"},{"issue":"1","key":"10.1016\/j.soc.2024.12.002_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0031-1272874","article-title":"Update on malignant pleural mesothelioma","volume":"32","author":"Campbell","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"issue":"21","key":"10.1016\/j.soc.2024.12.002_bib35","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","article-title":"Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial","volume":"26","author":"Simon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.12.002_bib36","doi-asserted-by":"crossref","first-page":"e232526","DOI":"10.1001\/jamanetworkopen.2023.2526","article-title":"Clinical outcomes associated with pembrolizumab monotherapy among adults with diffuse malignant peritoneal mesothelioma","volume":"6","author":"Marmarelis","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.soc.2024.12.002_bib37","doi-asserted-by":"crossref","first-page":"e2119934","DOI":"10.1001\/jamanetworkopen.2021.19934","article-title":"Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma","volume":"4","author":"Raghav","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.soc.2024.12.002_bib38","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.soc.2024.12.002_bib39","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1245\/s10434-024-15506-3","article-title":"Analysis of treatment strategies and outcomes in malignant peritoneal mesothelioma: insights from a multi-center study","volume":"31","author":"Ya\u015far","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2024.12.002_bib40","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2024.12.002_bib41","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1245\/s10434-014-3977-y","article-title":"Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome","volume":"22","author":"Ihemelandu","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.soc.2024.12.002_bib42","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1245\/s10434-023-13973-8","article-title":"2022 PSOGI consensus on HIPEC regimens for peritoneal malignancies: diffuse malignant peritoneal mesothelioma","volume":"30","author":"Kepenekian","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.soc.2024.12.002_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4149\/neo_2014_053","article-title":"Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma","volume":"61","author":"Kaya","year":"2014","journal-title":"Neoplasma"},{"issue":"4","key":"10.1016\/j.soc.2024.12.002_bib44","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jso.27301","article-title":"Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes","volume":"128","author":"Deban","year":"2023","journal-title":"J\u00a0Surg Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:46:31Z","timestamp":1750862791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320724000887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1055320724000887"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2024.12.002","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapy and Surgical Management of Peritoneal Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2024.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}